Cargando…
Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats
In this study was evaluated the chronic cardiac effects of a formulation developed by including angiotensin(Ang)-(1–7) in hydroxypropyl β-cyclodextrin (HPβCD), in infarcted rats. Myocardial infarction (MI) was induced by left coronary artery occlusion. HPβCD/Ang-(1–7) was administered for 60 days (7...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296310/ https://www.ncbi.nlm.nih.gov/pubmed/22482038 http://dx.doi.org/10.1155/2012/795452 |
_version_ | 1782225705981968384 |
---|---|
author | Marques, Fúlvia D. Melo, Marcos B. Souza, Leandro E. Irigoyen, Maria Claúdia C. Sinisterra, Rúben D. de Sousa, Frederico B. Savergnini, Sílvia Q. Braga, Vinícius B. A. Ferreira, Anderson J. Santos, Robson A. S. |
author_facet | Marques, Fúlvia D. Melo, Marcos B. Souza, Leandro E. Irigoyen, Maria Claúdia C. Sinisterra, Rúben D. de Sousa, Frederico B. Savergnini, Sílvia Q. Braga, Vinícius B. A. Ferreira, Anderson J. Santos, Robson A. S. |
author_sort | Marques, Fúlvia D. |
collection | PubMed |
description | In this study was evaluated the chronic cardiac effects of a formulation developed by including angiotensin(Ang)-(1–7) in hydroxypropyl β-cyclodextrin (HPβCD), in infarcted rats. Myocardial infarction (MI) was induced by left coronary artery occlusion. HPβCD/Ang-(1–7) was administered for 60 days (76 μg/Kg/once a day/gavage) starting immediately before infarction. Echocardiography was utilized to evaluate usual cardiac parameters, and radial strain method was used to analyze the velocity and displacement of myocardial fibers at initial time and 15, 30, and 50 days after surgery. Real-time PCR was utilized to evaluate the fibrotic signaling involved in the remodeling process. Once-a-day oral HPβCD/Ang-(1–7) administration improved the cardiac function and reduced the deleterious effects induced by MI on TGF-β and collagen type I expression, as well as on the velocity and displacement of myocardial fibers. These findings confirm cardioprotective effects of Ang-(1–7) and indicate HPβCD/Ang-(1–7) as a feasible formulation for long-term oral administration of this heptapeptide. |
format | Online Article Text |
id | pubmed-3296310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32963102012-04-05 Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats Marques, Fúlvia D. Melo, Marcos B. Souza, Leandro E. Irigoyen, Maria Claúdia C. Sinisterra, Rúben D. de Sousa, Frederico B. Savergnini, Sílvia Q. Braga, Vinícius B. A. Ferreira, Anderson J. Santos, Robson A. S. Int J Hypertens Research Article In this study was evaluated the chronic cardiac effects of a formulation developed by including angiotensin(Ang)-(1–7) in hydroxypropyl β-cyclodextrin (HPβCD), in infarcted rats. Myocardial infarction (MI) was induced by left coronary artery occlusion. HPβCD/Ang-(1–7) was administered for 60 days (76 μg/Kg/once a day/gavage) starting immediately before infarction. Echocardiography was utilized to evaluate usual cardiac parameters, and radial strain method was used to analyze the velocity and displacement of myocardial fibers at initial time and 15, 30, and 50 days after surgery. Real-time PCR was utilized to evaluate the fibrotic signaling involved in the remodeling process. Once-a-day oral HPβCD/Ang-(1–7) administration improved the cardiac function and reduced the deleterious effects induced by MI on TGF-β and collagen type I expression, as well as on the velocity and displacement of myocardial fibers. These findings confirm cardioprotective effects of Ang-(1–7) and indicate HPβCD/Ang-(1–7) as a feasible formulation for long-term oral administration of this heptapeptide. Hindawi Publishing Corporation 2012 2012-02-09 /pmc/articles/PMC3296310/ /pubmed/22482038 http://dx.doi.org/10.1155/2012/795452 Text en Copyright © 2012 Fúlvia D. Marques et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Marques, Fúlvia D. Melo, Marcos B. Souza, Leandro E. Irigoyen, Maria Claúdia C. Sinisterra, Rúben D. de Sousa, Frederico B. Savergnini, Sílvia Q. Braga, Vinícius B. A. Ferreira, Anderson J. Santos, Robson A. S. Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats |
title | Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats |
title_full | Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats |
title_fullStr | Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats |
title_full_unstemmed | Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats |
title_short | Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats |
title_sort | beneficial effects of long-term administration of an oral formulation of angiotensin-(1–7) in infarcted rats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296310/ https://www.ncbi.nlm.nih.gov/pubmed/22482038 http://dx.doi.org/10.1155/2012/795452 |
work_keys_str_mv | AT marquesfulviad beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats AT melomarcosb beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats AT souzaleandroe beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats AT irigoyenmariaclaudiac beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats AT sinisterrarubend beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats AT desousafredericob beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats AT savergninisilviaq beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats AT bragaviniciusba beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats AT ferreiraandersonj beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats AT santosrobsonas beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats |